'Not game-changing': Boehringer's phase 3 lung data get muted response from analysts
Analysts have given muted reception to Boehringer Ingelheim’s long-awaited phase 3 lung disease data, calling nerandomilast “a step forward but not game-changing.”
Analysts have given muted reception to Boehringer Ingelheim’s long-awaited phase 3 lung disease data, calling nerandomilast “a step forward but not game-changing.”
